Your email has been successfully added to our mailing list.

×
-0.0173410404624276 -0.00578034682080925 -0.0404624277456647 -0.0520231213872832 0.0173410404624278 -0.0578034682080924 -0.225433526011561 -0.101156069364162
Stock impact report

Alterity Therapeutics up big on advancement of ATH434 for Parkinsonian disorder [Seeking Alpha]

Alterity Therapeutics Limited - American Depositary Shares (ATHE)  More Company Research Source: Seeking Alpha
PDF Alterity Therapeutics (NASDAQ:ATHE71%receivingAlterity reached agreement with the agency on the non-clinical investigations required to support the mid-stage study, along with patient population, safety monitoring plan, and strategy for evaluating drug exposure during the trial.The agency and Alterity will work together to develop an endpoint that is best suited for the MSA patients.The company is also pursuing approvals in Europe and Australia. [Read more]
Impact snapshot Event time: ATHE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ATHE alerts
from News Quantified
Opt-in for
ATHE alerts

from News Quantified
Opt-in for
ATHE alerts

from News Quantified